Virtus ETF Advisers LLC Increases Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Virtus ETF Advisers LLC boosted its position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 30.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 35,789 shares of the company’s stock after acquiring an additional 8,457 shares during the quarter. Virtus ETF Advisers LLC owned 0.08% of Y-mAbs Therapeutics worth $280,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. KLP Kapitalforvaltning AS purchased a new position in shares of Y-mAbs Therapeutics during the 4th quarter valued at about $46,000. Wells Fargo & Company MN lifted its holdings in shares of Y-mAbs Therapeutics by 54.1% in the 4th quarter. Wells Fargo & Company MN now owns 17,458 shares of the company’s stock worth $137,000 after acquiring an additional 6,131 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Y-mAbs Therapeutics by 30.7% in the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company’s stock valued at $139,000 after purchasing an additional 4,163 shares in the last quarter. XTX Topco Ltd grew its holdings in shares of Y-mAbs Therapeutics by 83.8% during the 4th quarter. XTX Topco Ltd now owns 20,768 shares of the company’s stock valued at $163,000 after purchasing an additional 9,468 shares during the last quarter. Finally, Principal Financial Group Inc. grew its stake in shares of Y-mAbs Therapeutics by 9.4% during the fourth quarter. Principal Financial Group Inc. now owns 22,197 shares of the company’s stock valued at $174,000 after buying an additional 1,903 shares during the last quarter. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Insider Activity

In related news, insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the transaction, the insider now directly owns 202,721 shares of the company’s stock, valued at $1,060,230.83. This trade represents a 5.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 22.50% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on YMAB. Wedbush restated an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, March 3rd. HC Wainwright dropped their price objective on Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Morgan Stanley decreased their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research note on Wednesday, March 5th. Bank of America cut shares of Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 price target for the company. in a research report on Tuesday, April 22nd. Finally, Truist Financial decreased their price objective on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, March 5th. Two research analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Y-mAbs Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $17.40.

Y-mAbs Therapeutics Price Performance

YMAB stock opened at $4.10 on Monday. The firm has a 50-day moving average of $4.87 and a 200 day moving average of $8.11. The company has a market cap of $185.39 million, a P/E ratio of -7.59 and a beta of 0.71. Y-mAbs Therapeutics, Inc. has a 1 year low of $3.84 and a 1 year high of $17.78.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The firm had revenue of $26.50 million during the quarter, compared to the consensus estimate of $26.70 million. During the same period in the prior year, the company posted ($0.02) EPS. On average, equities research analysts expect that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.